Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma

Neuro-Oncology

Volumn 18, Issue 3, 2016, Pages 401-407

  Furtner, Julia ^a   Schöpf, Veronika ^b,c   Seystahl, Katharina ^d   Le Rhun, Emilie ^e,f,g   Rudà, Roberta ^h   Roelcke, Ulrich ⁱ   Koeppen, Susanne ^j   Berghoff, Anna Sophie ^a   Marosi, Christine ^a   Clement, Paul ^k   Faedi, Marina ^l   Watts, Colin ^m   Wick, Wolfgang ^d,n,o   Soffietti, Riccardo ^h   Weller, Michael ^a   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c BIOTECHMED GRAZ   (Austria)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g Oscar Lambret center   (France)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ CANTONAL HOSPITAL AARAU   (Switzerland)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

anaplastic meningioma; anti angiogenesis; atypical meningioma; bevacizumab; chemotherapy

Indexed keywords

BEVACIZUMAB; CYTOTOXIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOSTATIN DERIVATIVE; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; EUROPE; HISTOPATHOLOGY; HUMAN; MENINGIOMA; NEURORADIOLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITUMORAL BRAIN EDEMA; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR VOLUME; AGED; BRAIN TUMOR; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; FEMALE; KINETICS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRAIN EDEMA; BRAIN NEOPLASMS; FEMALE; HUMANS; KINETICS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84960112025     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov183     Document Type: Article

References (25)

1. Wöhrer A, Waldhör T, Heinzl H, et al. The Austrian brain tumour registry: A cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95(3):401-411.
2. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(suppl.):1-63.
3. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumors of th Central Nervous System. 4th ed. Lyon, France: IARC Press; 2007.
4. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107(2): 315-321.
5. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004; 13(7):1210-1212.
6. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3): 271-276.
7. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;15(8):2146-2151.
8. Grunberg SM,Weiss MH, Russell CA, et al. Long-termadministration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727-733.
9. Johnson DR, Kimmel DW, Burch PA, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530-535.
10. Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990; 8(1):61-65.
11. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012; 109(1):187-193.
12. Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009;11(6): 853-860.
13. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211-217.
14. Kaley T, Barani I, Chamberlain MC, et al. Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: A RANO review. Neuro Oncol. 2014;16(6):829-840.
15. Rorden C, Karnath HO, Bonilha L. Improving lesion-symptom mapping. J Cogn Neurosci. 2007;19(7):1081-1088.
16. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969-973.
17. Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117(1): 93-101.
18. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116-121.
19. Puchner MJA, Hans VH, Harati A, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21(12): 2445-2446.
20. Baumgarten P, Brokinkel B, Zinke J, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol. 2013;28(9):1157-1166.
21. Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012;31(5):352-360.
22. Mautner VF, Nguyen R, Knecht R, et al. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol. 2010;21(11):2294, 2295.
23. Nassehi D, Sørensen LP, Dyrbye H, et al. Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway. APMIS. 2013; 121(11):1025-1036.
24. Iwado E, Ichikawa T, Kosaka H, et al. Role of VEGF and matrix metalloproteinase-9 in peritumoral brain edema associated with supratentorial benign meningiomas. Neuropathology. 2012; 32(6):638-646.
25. Schmid S, Aboul-Enein F, Pfisterer W, et al. Vascular endothelial growth factor: The major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery. 2010;67(6):1703-1708.